Prestige Consumer Healthcare Inc. $PBH Shares Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd raised its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 899.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 32,635 shares of the company’s stock after purchasing an additional 29,369 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Prestige Consumer Healthcare were worth $2,036,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Caitong International Asset Management Co. Ltd increased its stake in Prestige Consumer Healthcare by 312.5% during the second quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock worth $26,000 after acquiring an additional 250 shares during the last quarter. First Horizon Corp purchased a new stake in shares of Prestige Consumer Healthcare in the 3rd quarter valued at approximately $32,000. Geneos Wealth Management Inc. raised its position in Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after purchasing an additional 269 shares during the period. Elevation Point Wealth Partners LLC acquired a new position in Prestige Consumer Healthcare during the second quarter worth $46,000. Finally, First Horizon Advisors Inc. increased its stake in Prestige Consumer Healthcare by 294.1% during the second quarter. First Horizon Advisors Inc. now owns 599 shares of the company’s stock worth $48,000 after purchasing an additional 447 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 719 shares of the business’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $60.00, for a total transaction of $43,140.00. Following the sale, the vice president directly owned 42,329 shares in the company, valued at approximately $2,539,740. The trade was a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.40% of the company’s stock.

Analyst Ratings Changes

PBH has been the topic of a number of recent research reports. Canaccord Genuity Group cut their target price on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Jefferies Financial Group cut their price target on Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a research report on Monday, October 27th. Oppenheimer decreased their price objective on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a report on Tuesday, October 21st. Finally, Zacks Research upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.33.

Prestige Consumer Healthcare Trading Down 1.1%

Shares of PBH stock opened at $63.18 on Thursday. The business’s fifty day moving average price is $62.32 and its 200 day moving average price is $64.48. The firm has a market capitalization of $3.04 billion, a PE ratio of 15.68, a P/E/G ratio of 2.01 and a beta of 0.40. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.70 and a quick ratio of 2.51. Prestige Consumer Healthcare Inc. has a 1-year low of $57.25 and a 1-year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, November 6th. The company reported $1.07 EPS for the quarter, topping the consensus estimate of $0.97 by $0.10. The company had revenue of $274.11 million for the quarter, compared to analyst estimates of $257.14 million. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The business’s revenue was down 3.4% on a year-over-year basis. During the same period in the previous year, the firm earned $1.09 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. As a group, sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).